The only weekly and monthly long-acting
individualised treatment for opioid dependence¹

About Buvidal

This section is intended for healthcare professionals prescribing or administering Buvidal for treatment of patients with opioid dependence.

We strongly recommend that the information is read alongside the Summary of Product Characteristics (SmPC) and the product Package Leaflet. Healthcare professionals working in Great Britain can find both of these on the Electronic Medicines Compendium (EMC) website medicines.org.uk.

Healthcare professionals working in Northern Ireland should access the SmPC and product Package Leaflet at the EMC Northern Ireland website, using the following link www.emcmedicines.com.

Licensed Indication:

Buvidal is indicated for the treatment of opioid dependence within a framework of medical, social and psychological support.

Treatment is intended for use in adults and adolescents aged 16 years or over.

Prescribing information can be found here.

Product Overview

Buvidal is available in weekly and monthly formulations.

These in turn are available in four doses as follows:

  • Weekly Buvidal is available in 8, 16, 24 and 32 mg doses
  • Monthly Buvidal is available in 64, 96, 128 and 160 mg doses

Both weekly and monthly Buvidal come in the form of a single use, pre-filled syringe for subcutaneous injection.

The injection must be administered by a qualified healthcare professional.

In the interests of healthcare professional and patient safety, the syringe features a safety device to prevent accidental needlestick injury post-injection.

Buvidal does not require cold storage and can be kept in a conventional controlled drugs cabinet. It has as shelf-life of three years.

1. Camurus. Buvidal Summary of Product Characteristics (SmPC).